Abstract

Different "Business Models" in CNS Drug Discovery/Development

Declan Jones, Neuroscience Therapeutic Area Lead, J&J London Innovation Centre

Janssen is focused on finding breakthrough treatments for Alzheimer's disease, mood disorders, psychosis and pain. Developing diagnostics and biomarkers is absolutely key to this strategy which requires access to the very best science to achieve this. Our goal is to leverage technologies in imaging, genomics, and associated biomarkers to provide early disease diagnostics and patient management programs. Along with a strong commitment to our internal research groups, we are dedicated to partnering with individuals and companies that want to work together to build the neuroscience treatments of tomorrow. One way of doing this is via the newly established Johnson & Johnson innovation centres in the major science and technology hubs, Boston, San Francisco, London and Shanghai (www.jnjinnovation.com).  Each regional centre has full and broad deal-making capabilities with flexibility to find suitable parnership structures, which can include licensing and acquisition of assets or technologies, academic partnerships,   public-private partnerships (including with other pharma partners, academics, biotechs, research councils or charities), opportunities to license out and reposition selected compounds in our neuroscience pipeline, or other innovative business structures, such as venture investments, option deals and risk-sharing partnerships. I will describe our approach to partnership within the neuroscience area, with specific examples in CNS biomarkers.